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Summary Childhood neuroblastoma tumours of the sympathetic nervous system show a remarkable clinical
heterogeneity ranging from spontaneous regression to unfavourable outcome despite intensive therapy.
Favourable neuroblastomas often express high levels of trkA mRNA, encoding the tyrosine kinase receptor for
nerve growth factor. We have investigated mRNA expression for the neurotrophin receptor trkC in 23 primary
neuroblastomas using a sensitive RNAase protection assay. TrkC expression was detected in 19 of these
tumours at highly variable levels with a 300-fold difference between the highest and lowest values. Significantly
higher levels of trkC mRNA were found in tumours from patients with favourable features such as low age
(P<0.012), favourable tumour stage (P<0.012) and favourable prognosis (P<0.05). Children with
intermediate or high trkC mRNA expression had better prognosis compared with those with low or
undetectable levels (83.3% vs 20%, P=0.005). Further characterisation of trkC mRNA expression by reverse
transcriptase-polymerase chain reaction (RT-PCR) showed that mRNA encoding the full-length cytoplasmic
tyrosine kinase domain of the receptor was only expressed in a subset of favourable tumours. These data show
that favourable neuroblastomas may express the full trkC receptor while advanced tumours, in particular
MYCN-amplified neuroblastoma, seem to either express no trkC or truncated trkC receptors of as yet
unknown biological function. These data are suggestive of a role for trkC and its preferred ligand
neutotrophin-3, NT-3, in neuroblastoma differentiation and/or regression.
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Neuroblastoma (NB) is a complex childhood tumour derived
from sympathoadrenal progenitors of the neural crest with a
broad clinical spectrum, including spontaneous regression of
widespread disease and poor outcome despite highly intensive
multimodal therapy. NB tumours are classified into localised
(stage 1 and 2), regional (stage 3) and metastatic (stage 4)
with an additional subset ofwidespread infant tumours (stage
4S), which often show spontaneous regression and/or
differentiation (Brodeur et al., 1993). Age at diagnosis is an
important factor related to prognosis, the majority of
neuroblastomas occurring under 1-2 years of age are of
stages 1, 2 or 4S with a favourable clinical outcome. Patients
over 1-2 years of age often present advanced tumours, and
in this group survival rates have not improved significantly
during recent years despite increasingly aggressive therapy.
The clinical heterogeneity of NB has stimulated an intensive
search for biological markers correlated with prognosis, in
order to allow, at an early stage the assessment of the
individual patient as having favourable or poor prognosis
respectively. Genomic amplification of the N-myc oncogene
(MYCN), is correlated with advanced stage and unfavourable
outcome (Brodeur et al., 1984; Schwab et al., 1983; Seeger et
al., 1985). Genetic aberrations found in NB include other
structural chromosomal abnormalities, in particular deletions
involving the short arm of chromosome 1 (Brodeur et al.,
1977). Recent data indicate that chromosome lp harbours
one or several tumour-suppressor genes that may be specific
for the development of unfavourable NB (Caron et al., 1995;
Martinsson et al., 1995; White et al., 1995).
Other biological markers of prognostic significance include
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neuropeptides (e.g. neuropeptide Y) (Kogner et al., 1990), ras
and src proteins (Bjelfman et al., 1990; Tanaka et al., 1991)
and neurotrophic factors and their receptors. Of the
receptors, the most promising ones are the nerve growth
factor (NGF) receptors trkA and p75LNGFR (Borello et al.,
1993; Kogner et al., 1993; Nakagawara et al., 1993; Suzuki et
al., 1993). TrkA encodes a receptor with tyrosine kinase
activity essential for NGF signal transduction and function
while the role of p75LNGFR in NGF signalling is still not fully
understood (Chao and Hempstead, 1995; Ibainez, 1995).
NGF, the first discovered member of the neurotrophin
family, is essential for differentiation and survival of
sympathetic neurons and it has been suggested that NGF
may be important for differentiation and regression of
tumours of neural crest origin (Kogner et al., 1993).
Introduction of a functional trkA cDNA into NB cell lines
allowed differentiation after NGF treatment indicating that
loss of functional NGF receptor expression may play an
important role in the behaviour of advanced NB (Matsush-
ima and Bogenmann, 1993; Poluha et al., 1995). In culture of
primary NB tumours expressing trkA, NGF induced terminal
differentiation, whereas NGF deprivation resulted in cell
death (Nakagawara et al., 1993). In agreement with this, trkA
expression has been found to be associated with young age at
diagnosis and non-advanced stages of NB tumours.
Simultaneous expression of trkA and p75LNGFR mRNA has
been shown to define a favourable subset of NB tumours
which either differentiate or regress spontaneously and/or
respond to therapy (Kogner et al., 1993; Nakagawara et al.,
1993). Analysis of trkA and p75 mRNA, combined with
analysis of DNA content in tumour cells, may predict clinical
outcome in most children with NB (Kogner et al., 1994).
The role of NGF and its receptors in NB has raised
interest in the possible participation of other members of the
neurotrophin family. Brain-derived neurotrophic factor
(BDNF) (Barde et al., 1982; Leibrock et al., 1989) and its
preferred receptor trkB (Glass et al., 1991; Klein et al., 1991)
have been shown to be expressed at high levels in many NBTrkC in neuroblastoma
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tumours with poor prognosis (Kaplan et al., 1993;
Nakagawara et al., 1994). In vitro studies on NB cell lines
have shown that BDNF increases NB cell survival, neurite
extension and stimulates invasiveness (Matsumoto et al.,
1995). Several tumours with amplification of MYCN and
poor clinical prognosis also express BDNF which may
constitute an autocrine or paracrine loop stimulating tumour
growth. TrkB can be expressed either as a full-length receptor
or in a truncated non-signalling form lacking the tyrosine
kinase domain (Klein et al., 1990; Middlemas et al., 1991).
Interestingly, maturing tumours appear more likely to express
the truncated form of this receptor (Nakagawara et al., 1994).
In this study we have investigated the mRNA expression
profile of the third member of the neurotrophin receptor
tyrosine kinase family, trkC, a receptor for neurotrophin-3
(NT-3) (Lamballe et al., 1991) which is involved in the
survival of subpopulations of neural crest and placode-
derived sensory neurons (Ernfors et al., 1994). Our results
indicate that higher levels of trkC mRNA expression
correlate significantly with localised disease stage, young
age and good prognosis, suggesting that, like trkA, trkC
could probably provide a useful marker in the clinical
evaluation of NB tumours. In addition, trkC mRNA found
in a few of the advanced unfavourable neuroblastomas was
of the truncated subtype, i.e. lacking the intracellular tyrosine
kinase domain. These data indicate that, although a few
aggressive neuroblastomas may express trkC receptors, these
are of the truncated types, suggesting a role for trkC
signalling in neuroblastoma regression and/or differentiation.
Materials and methods
Patient material and sample handling
Twenty-four children with neuroblastoma diagnosis accord-
ing to International Neuroblastoma Staging System (INSS)
criteria (Brodeur et al., 1993) including tumours of all five
clinical stages (4S, 1, 2, 3 and 4) were included in the study,
based on availability of tumour tissue for trkC analysis
(Table I). Primary tumour tissue was available from 23
children, while from one, only relapsing tumour tissue was
analysed. In addition to primary tumours, a metastasis was
analysed from one child, and from another, residual tumour
tissue obtained after chemotherapy could be compared with
primary tumour tissue removed before therapy. Data from
the 23 children with primary tumours were used for
calculation of correlations with clinical features and
prognosis. Seven children died during follow-up after 0.5-
11 months (median 6 months), five owing to tumour
progression and two owing to toxic and/or surgical
complications (Table I). Survival probability for the whole
group of 23 children was 69.6% (standard error 9.6%). The
16 survivors were followed for 18-52 months (median 33
months). Tumour tissue from all patients was surgically
resected and immediately frozen at -70°C until analysis.
Tumour cell content of the samples was assessed histologi-
cally in tumour tissue adjacent to that used for RNA
extraction.
Statistical calculations
The Wilcoxon-Mann-Whitney rank sum test was used for
the comparison of two independent samples. Survival
probability was calculated using the Kaplan-Meier method
and compared using the Mantel-Haenszel log-rank test.
DNA cloning
A cDNA fragment encoding the transmembrane domain of
human trkC (htrkC), was amplified by RT-PCR on human
cortex total RNA using a 5' rat derived primer
(GGAATTCCATTTGGGGTATCCATAGCTG) and a 3'
porcine-derived primer (GGGAAGCTTCTTCCCAAAG-
GCTCCCTCAC) yielding an approximately 380 bp-long
Table I Patient material and trkC expression
Patient Age Follow-up TrkC
number Stagea (months) Outcome (months) TrkAb MYCNC indexd
1 4S 0 NEDe 26+ + < 3 3
2 4S 0 NED 48+ + < 3 0.42
3 4S 5 NED 43+ NA' < 3 0.025
4 4S 5 NED 35+ + < 3 0.17
5 1 0 NED 52+ + <3 0.93
6 1 1 Deadg 0.5 + <3 0.59
7 1 9 NED 29+ + < 3 0.67
8 1 12 NED 36+ + <3 0.023
9 1 17 NED 27+ + < 3 1.5
01 2A 33 NED 19+ + < 3 0.045
11 2A 60 NED 21+ NA <3 0.15
12 2B 31 NED 37+ + < 3 0.12
13 3 0 Dead 0.5 + < 3 0
14 3 2 NED 18+ <3 0.25
15 3 6 NED 47+ + < 3 0.08
16 3 7 NED 25+ < 3 0.34
17 3 10 NED 37+ + <3 0.09
18 3 11 NED 31+ + <3 0
19 4 10 DODh 10 >10 0.32
20A 4 19 DOD 4 - >10 0.17
20WB 4(res) 19 DOD 4 - > 10 0
21 4 30 DOD 11 - < 3 0
22 4 50 DOD 6 - >10 0
23A 4 137 DOD 8 - >10 0.01
23Bj 4 (met) 137 DOD 8 - >10 0
24k 1 (rel) 30 NED 12+ - <3 0.04
aAccording to International Neuroblastoma Staging System
(Broduer et al., 1993). bTrka mRNA expression by Northern blot
analysis (Kogner et al., 1993). CMYCN gene copy number per haploid
genome by Southern blot analysis (Seeger et al., 1985). dTrkC
index=TrkC mRNA/GAPDH mRNA. 'NED, no evidence of
disease. rNA, not analysed. gDead, dead from toxic or post-surgical
complications. hDOD, dead of disease. '20B, residual tumour tissue
afterchemotherapy.j23B, metastatictissue. kRelapsed tumourtissue at
primary site.
fragment. It was subsequently subcloned into pBS KS +
(Stratagene). DNA sequencing revealed a sequence with
significant homology to trkC sequences previously isolated
from other species. A 190 bp-long cDNA fragment of the
human glyceraldehyde-3-phosphate dehydrogenase (hGA-
PDH) gene spanning bases 675 to 865 was amplified by
RT-PCR on human cortex total RNA using a 5' primer
(CAGAATTCTGCCTCTACTGGCGCT) and a 3' primer
(CAGGATCCGACGCCTGCTTCACCA) and subcloned
into pBS KS+.
RNA preparation
Total RNA was prepared by homogenisation in 4 M
guanidine isothiocyanate followed by either centrifugation
through a caesium chloride cushion (Chirgwin et al., 1979) or
treatment with sodium acetate (pH 4.0) and a phenol-
chloroform extraction (Trupp et al., 1995) depending on the
amount of tissue.
Northern blots
Equal amounts (20 pg) of total RNA were separated in a
denaturing 1% agarose gel containing 0.7% formaldehyde
and 0.1 mg ml-' ethidium bromide. After electrophoresis the
gels were examined under UV light to control for equal RNA
loading in each sample. RNA was blotted onto nitrocellulose
membranes (Hybond C-extra, Amersham) and hybridised to
a 2.7 kb EcoRI fragment from a human trkA cDNA clone
(Martin-Zanca et al., 1991). Probes were labelled with a-[32P]-
dCTP by random priming or nick translation to a specific
activity of 109 c.p.m. jug-'. Hybridisation was performed
overnight in 4 x sodium saline citrate (SSC)(1 x SSC is 0.15 M
sodium chloride, 0.015 M sodium citrate pH 7.0), 40%
formamide, 1 x Denhardt's solution and 10% dextranTrkC in neuroblastoma
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sulphate. Filters were washed at 56°C in 0.1 x SSC, 0.1%
sodium dodecyl sulphate (SDS) and exposed to Kodak X-
Omat films at -70°C. Equal conditions were used for
hybridisation with the isolated htrkC probe described above.
RNAse protection analysis
Template plasmids were linearised by the appropriate
restriction enzyme (EcoRI in the case of trkC and XhoI in
GAPDH) according to the orientation in the plasmid, after
which anti-sense single strand ribo probes were generated
according to the manufacturer's protocol (Ambion). To
assure that equal amounts of RNA were loaded in every
well a probe derived from GAPDH, a constitutively
expressed gene, was used as an internal control. Gels were
exposed for 24 to 72 h on Kodak X-Omat AR films at
-70°C and later scanned in an image analyser (Leica). TrkC
index was calculated as the ratio of the optical densities of
the trkC band to the GAPDH band, and it was used as an
estimate of the trkC mRNA expession. TrkC index values
represent the mean of at least two independent determina-
tions (Table I).
TrkC kinase domain mRNA detection by RT-PCR
To amplify the htrkC kinase domain, a 5' primer carrying a
BamHI restriction site (GCGGATCCTATGGAGTGT-
GCGGCGA) and a 3' primer (CGGAATTCGGTGTG-
TCCTCCCACC) including an EcoRI restriction site were
designed, and were expected to give two bands of 350 bp and
390 bp respectively corresponding to different splice variants
(Shelton et al., 1995). RT-PCR was performed on total
RNA from tumours using a Gene-Amp (Perkin-Elmer) RT-
PCR kit with the previously described hGAPDH primers
included in the same reaction. The reverse transcription step
was performed at 50°C for 3 min followed by 70°C for
14 min. The PCR steps were run with three 1-min rounds of
annealing at 50°C followed by 39 1-min rounds at 55°C.
Elongation was performed for 1 min at 60°C. The PCR
products were separated on a 3% agarose gel. Only two
bands were observed, a 190 bp band corresponding to the
hGAPDH and another one of approximately 360 bp. The
latter was purified, cleaved with EcoRI and BamHI and
subsequently subcloned into pBs KS+. DNA sequencing
demonstrated its identity as the kinase region of htrkC
(Shelton et al., 1995).
Results
Isolation of a human trkC probe
A DNA fragment from the human trkC gene was cloned by
RT-PCR from human cortex total RNA using degenerate
primers derived from conserved regions in the transmem-
brane domains of the rat and pig trkC genes. A fragment of
the expected size was subsequently subcloned and sequenced.
During the preparation of this manuscript a full-length
sequence of human trkC was reported (Shelton et al., 1995)
which was identical to that of our clone in the transmem-
brane region.
a
htrkC 1 1kb-_
5 kb-_
2 kb-_
b
htrkC-"
hGAPDH--
Rat
brain 21 9 13 1 19 2 15
ctrIctx 3 7 22 1 18 4208 20A15 14 21 2 1613
Figure 1 (a) Northern blot of total RNA from neuroblastomas
of indicated patients hybridised with the htrkC probe. Rat brain
RNA was run as a control. Note that an 11 kb fragment,
encoding one of the htrkC splicing variants, appears only in one
lane (no. 1). The 5kb bands in the autoradiogram represent cross-
hybridisation of the probe to rRNA. (b) RNAase protection of
total NB RNAs. Yeast RNA and human cortex RNA were used
as negative and positive controls respectively. Protected bands
corresponding to human trkC and human GAPDH are indicated.
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Expression of trkC mRNA in NB tumours
Total RNA was extracted from NB tumour samples, the NB
cell line SH-SY5Y and from normal human cerebral cortex.
Initial Northern blot analysis showed that levels of trkC
mRNA were below the detection limit in most samples.
However, one favourable stage 4S tumour, showed significant
trkC mRNA expression (no. 1, Figure la). This prompted us
to develop a RNAse protection assay for human trkC
mRNA to achieve higher sensitivity. TrkC mRNA expres-
sion could then be detected in the majority of tumours
analysed (19 of 23 primary NB and one relapsed tumour). A
trkC index was obtained to enable quantitative comparisons,
Figure 2 Summary of trkC mRNA expression in primary
neuroblastoma tumours of different clinical stages (4S, 1, 2, 3
and 4 respectively, according to INSS; Brodeur et al., 1993). TrkC
index (Trkc mRNA/GAPDH mRNA, in logarithmic scale) was
higher in favourable stages (4S, 1, 2) compared with advanced
stages (3 and 4, P<0.012). TrkC index was higher in tumours
from children with favourable outcome (open symbols) than from
children who died (filled and dotted symbols, P<0.05). 0 and *,
primary neuroblastomas not amplified for the MYCN oncogene;
*, MYCN-amplified primary neoroblastomas; O, relapsed
tumour tissue; 0 and *, tumours from children dead from
tumour progression; (0, children dead owing to toxic or post-
surgical complications; CTRL, control cells (human cerebral
cortex, A; SH-SY5Y cells, V).TrkC in neuroblastoma
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as described in Materials and methods (Figure lb). The trkC
index was highly variable in the different tumours, ranging
from 0 to 3.0 (Table I and Figure 2). TrkC mRNA
expression could be detected in all tumours of favourable
stages (1, 2 and 4S). Four tumours showed higher trkC index
than the positive control (cerebral cortex, index 0.6). These
tumours with the highest levels were of stage 1 and 4S (nos.
1, 5, 7 and 9). In contrast, the lowest levels were seen in
tumours of stages 3 and 4 including the four tumours (13, 18
21 and 22) in which trkC mRNA was not detected. There
were however tumours of favourable stages that expressed
relatively low levels of trkC mRNA (e.g. nos. 3 and 8) and
also a few advanced tumours with high levels (14, 16, 19 and
20) (Figure 2). In the neuroblastoma cell line SH-SY5Y, low
levels of trkC mRNA could be detected (Figure 2). As
expected, trkC mRNA was highly expressed in normal brain
tissue (Figure lb). A relapsing stage 1 tumour showed a
relatively low level of trkC expression (no. 24, Figure 2).
Residual tumour tissue after preoperative chemotherapy and
metastasis did not show detectable trkC (20B and 23B
respectively, Table I).
Correlation between trkC mRNA expression and clinical
tumour stage, age andfavourable prognosis
TrkC index was higher in primary tumours of favourable
stage 1, 2 and 4S (n= 12, 0.3: 0.05-0.67, median: lower-
upper quartile) compared with advanced tumours (n = 11,
0.08: 0.0-0.12, P<0.012). Children < 18 months at diagnosis
(n = 15) had higher trkC index than the older children (n =8,
0.32: 0.08-0.53 vs 0.03: 0.0-0.12, P<0.012). Also using cut
off levels at 12 and 24 months of age respectively, showed
significantly higher trkC index in younger children. Children
with favourable clinical outcome had higher index than seven
who died during follow-up (0.16: 0.05-0.42 vs 0.01: 0.0-
0.07, P<0.05). When testing for different cut off levels, trkC
index at 0.01 or lower gave the best discrimination
concerning outcome in this limited material. Hence, survival
probability according to Kaplan-Meier analysis showed that
five children with very low or undetectable trkC expression
(index 0.01 or lower) had a significantly poorer prognosis
than the remaining 18 children (survival probability
20+17.9% vs 83.3+8.8%, respectively, both at 24 months,
P=0.005) (Figure 3). The subset of four children with trkC
index higher than cerebral cortex (>0.6) had an excellent
outcome with all surviving.
Correlation between trkC mRNA expression and trkA
expression and MYCN amplification
Results on trkA mRNA expression analysed by Northern
blotting were available for 21 primary tumours and have
been published in part previously (Kogner et al., 1993) (Table
I). TrkA expression in this material correlated significantly
with favourable tumour stage, young age, absence of MYCN
amplification and good prognosis. However, in the whole
material there was only a non-significant trend towards
association of trkA expression and high trkC index. All
tumours with high trkC index (>0.6) showed concomitant
trkA expression.
Results on MYCN amplification analysed by Southern
blotting (Seeger et al., 1985) were available for all tumours
and have been reported previously (Kogner et al., 1993;
Martinsson et al., 1995) (Table I). No significant difference in
the level of trkC expression could be detected between
MYCN-amplified tumours and those not amplified for
MYCN (Table I and Figure 2). This could have been owing
to the limited number of tumours that showed MYCN
amplification (n=4). Of particular interest therefore was to
analyse whether favourable tumours and unfavourable
MYCN-amplified tumours expressed similar isoforms of the
trkC receptor.
Expression offull-length trkC mRNA in low stage tumours
Full-length human trkC is present as several splice variants,
depending on the presence or absence of small insertions in
the kinase domain (Tsoulfas et al., 1993; Valenzuela et al.,
1993). These insertions are absent in the functional form of
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Figure 3 Survival probability according to Kaplan-Meier for 18
children with primary neuroblastoma tumours with intermediate
or high trkC mRNA expression [trkC index <0.01, ( ),
survival probability 83.3 +8.8%] compared with five children with
very low or undetectable trkC expression [trkC index <0.01,
(- - -), survival probability 20+17.9%, P=0.005, Mantel-
Haenszel log-rank test].
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Figure 4 RT-PCR analysis on total RNA from NB tumours,
using primers specific for the htrkC kinase region. hGAPDH
primers were run in the same reactions as a control. Samples,
including tumours from all stages were separated on a 3%
agarose gel. Molecular weight marker (pBs KS +/HpaII) denoted
by m. A 190bp-long fragment corresponding to hGAPDH is seen
in all lanes. (a) Tumours with favourable outcome; in four
tumours, an approximately 360bp-long amplified fragment
encoding the htrkC kinase region could be detected. (b)
Advanced tumours; no trkC product could be amplified in any
of the unfavourable tumours.
U)the human trkC receptor (Shelton et al., 1995). Primers for
RT-PCR were designed to differentiate among these splice
variants. An amplified product corresponding to the
predicted trkC kinase region without the insertions could
readily be detected in three stage 1 tumours and one
favourable stage 3 tumour (nos. 1, 2, 7 and 16 respectively,
Figure 4a). No PCR product could be seen in any of the
unfavourable tumours tested (Figure 4b). These results
indicate that functional full-length receptors are present in
the most benign tumours and that the high trkC mRNA
levels detected in some of the advanced stages (e.g.
MYCN-amplified tumours 19 and 20A) represent expres-
sion of truncated forms of trkC lacking the tyrosine kinase
domain.
Discussion
Neurotrophic factors and their receptors have been suggested
as playing significant roles in neuroblastoma tumour
persistence, differentiation and regression. The results
presented here show that high levels of trkC mRNA are
present in tumours from younger children with non-advanced
tumours and favourable prognosis. Thus, an index of trkC
mRNA expression may provide an additional prognostic
indicator in the assessment of these children. Furthermore, it
was shown that more favourable tumours prone to regression
or differentiation express the tyrosine kinase domain of the
receptor necessary for biological function. The absence of
full-length trkC mRNA expression in aggressive MYCN-
amplified tumours may suggest a role of trkC in
neuroblastoma tumour behaviour.
Expression of the NGF receptors trkA and p75LNGFR
has been shown to be a good prognostic marker of
benign NB tumours, while trkB appears to be expressed
in NB tumours with poor prognosis. TrkC expression in
NB has previously been analysed by Nakagawara et al.
(1994) by Northern blotting using a rat probe, and found
no detectable trkC mRNA expression. In the present
study, trkC mRNA expression could be detected in a
majority (20/24) of NB tumours using a very sensitive
RNAase protection assay. A statistically significant
positive correlation could be found between higher trkC
index in primary tumours and young age, favourable
stage and good prognosis. NB cell lines are usually
derived from poor prognosis NB tumours and in
accordance with this SH-SY5Y cells showed an almost
undetectable expression of trkC mRNA. NB tumours with
a trkC index higher than cerebral cortex had an excellent
prognosis. A concomitant expression of trkA mRNA and
detectable trkC mRNA was found in all localised tumours
(stage 1 and 2) and 4S tumours prone to spontaneous
differentiation or regression. TrkC mRNA expression was,
however, not significantly correlated with trkA mRNA
expression nor MYCN amplification. This may in part be
due to the sample size, and also related to the fact that
some unfavourable tumours with MYCN amplification
and absence of trkA mRNA expression showed a
relatively high trkC index but no expression of the trkC
tyrosine kinase domain. Nevertheless trkC index and trkA
expression were equally significant as prognostic indica-
tors. TrkA expression identified two different subgroups
(14 positive tumours with 85.7% survival probability and
seven negative tumours with 28.6% survival, P=0.016)
similar to trkC index more than 0.01 or not (83.3% vs
20% respectively, P=0.005) (Figure 3). A more definite
cut-off level for trkC index must be based on a larger
sample and tested prospectively. The present material is
too limited to allow firm conclusions concerning the use
of trkC as a prognostic indicator in neuroblastoma. Of
particular interest would be to study trkC mRNA
expression in the limited subset of localised tumours
showing progression or the metastatic tumours responding
favourably to therapy. Unfortunately, none of these
TrkC in neuroblastoma
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Table II Neurotrophin receptor mRNA expression in neuroblasto-
ma
p75LNGFR TrkA TrkB TrkC
Favourable + + Truncated Full length/
tumours truncated
Unfavourable Full length -/truncated
tumours
+, Expressed; -, not expressed
tumours were available in the present material. Both
metastatic stage 4 and presence of MYCN amplification
were more sensitive in predicting poor outcome in this
study than absence of trkA mRNA expression and low
trkC index respectively.
Interestingly, during the course of this study, results were
published on trkC mRNA expression in medulloblastoma
tumours, the most common intracranial childhood tumour
(Segal et al., 1994). It was shown that high trkC mRNA
levels were positively correlated with favourable prognosis.
This, together with the results presented here, indicate that
trkC analysis may have prognostic significance and may be
indicative of differentiation in several neuronal tumours.
Similarly, in another recent report published after completion
of the present study, trkC protein was detected by
immunohistochemistry in NB tumours (Hoehner et al.,
1995). It was found that the more differentiated tumour
cells stained most intensely for trkC but there was no
significant correlation with tumour stage or patient prog-
nosis.
Combining our own present and previous results (Kogner
et al., 1993) with those from other groups (Borello et al.,
1993; Kaplan et al., 1993; Matsumoto et al., 1995;
Nakagawara et al., 1994; Suzuki et al., 1993) a specific
pattern of neurotrophin receptor expression in various
neuroblastoma tumours emerges. Favourable neuroblastoma
tumours express trkA together with p75LNGFR and sometimes
full-length trkC, but only truncated trkB. On the other hand,
aggressive NB and MYCN-amplified tumours in particular,
lack trkA and p75LNGFR expression while they may coexpress
full-length trkB with its primary ligand BDNF together with
either no trkC or truncated trkC (Table II). The functional
significance of these patterns of expression of neurotrophin
receptors in NB remains to be fully defined. It was recently
suggested that neurotrophic factors could be provided to
differentiating tumour cells by infiltrating normal Schwann
cells that can often be found in maturing NB (Ambros and
Ambros, 1995). NGF and its receptors are suggested to play
a part in tumour differentiation and regression or apoptosis
(Matsushima and Bogenmann, 1993; Nakagawara et al.,
1993; Poluha et al., 1995) while the trkB-BDNF autocrine
loop has been proposed to support tumour survival and
invasiveness (Kaplan et al., 1993; Matsumoto et al., 1995;
Nakagawara et al., 1994). Additional studies are necessary to
establish the functional role of the different forms of trkC
receptors and their primary ligand NT-3 in NB cells. A full-
length, signalling trkC receptor may conceivably play a role
in differentiation/regression of favourable NB. However, it
can still be that the neurotrophins and their receptors may
merely be markers reflecting different states of tumour
aggresiveness.
In summary, we have shown that trkC mRNA expression
can be detected in most neuroblastoma tumours by a
sensitive RNAase protection assay. Higher trkC mRNA
expression was found in tumours from children of young
age with favourable clinical tumour stage and good
prognosis. The presence in some favourable tumours of
full-length trkC receptors as detected by RT-PCR suggests
that trkC may have a functional role in a subset of
favourable neuroblastomas prone to undergo differentiation
and/or apoptosis.TrkC i msw
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RT-PCR, reverse transcriptase- polymerase chain reaction; NB,
neuroblastoma; MYCN, N-myc oncogene; NGF, nerve growth
factor; BDNF, brain-derived neurotrophic factor, NT-3, neuro-
trophin-3; INSS, International Neuroblastoma Staging System;
SSC, sodium saline citrate; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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